- Home
- TLSA vs ACHV Comparison
TLSA vs ACHV Comparison
Compare TLSA & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- ACHV
- Stock Information
- Founded
- TLSA 2013
- ACHV N/A
- Country
- TLSA United Kingdom
- ACHV Canada
- Employees
- TLSA N/A
- ACHV N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TLSA Health Care
- ACHV Health Care
- Exchange
- TLSA Nasdaq
- ACHV Nasdaq
- Market Cap
- TLSA 87.8M
- ACHV 72.5M
- IPO Year
- TLSA 2000
- ACHV N/A
- Fundamental
- Price
- TLSA $1.57
- ACHV $2.35
- Analyst Decision
- TLSA
- ACHV Strong Buy
- Analyst Count
- TLSA 0
- ACHV 3
- Target Price
- TLSA N/A
- ACHV $14.33
- AVG Volume (30 Days)
- TLSA 460.2K
- ACHV 178.2K
- Earning Date
- TLSA 05-20-2025
- ACHV 05-13-2025
- Dividend Yield
- TLSA N/A
- ACHV N/A
- EPS Growth
- TLSA N/A
- ACHV N/A
- EPS
- TLSA N/A
- ACHV N/A
- Revenue
- TLSA N/A
- ACHV N/A
- Revenue This Year
- TLSA N/A
- ACHV N/A
- Revenue Next Year
- TLSA N/A
- ACHV N/A
- P/E Ratio
- TLSA N/A
- ACHV N/A
- Revenue Growth
- TLSA N/A
- ACHV N/A
- 52 Week Low
- TLSA $0.54
- ACHV $1.84
- 52 Week High
- TLSA $1.91
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- TLSA 64.57
- ACHV 46.09
- Support Level
- TLSA $1.49
- ACHV $2.32
- Resistance Level
- TLSA $1.78
- ACHV $2.69
- Average True Range (ATR)
- TLSA 0.18
- ACHV 0.18
- MACD
- TLSA 0.04
- ACHV 0.02
- Stochastic Oscillator
- TLSA 71.23
- ACHV 17.07
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.